Aldeyra The (ALDX) - Total Liabilities
Based on the latest financial reports, Aldeyra The (ALDX) has total liabilities worth $28.56 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aldeyra The - Total Liabilities Trend (2011–2024)
This chart illustrates how Aldeyra The's total liabilities have evolved over time, based on quarterly financial data. See ALDX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Aldeyra The Competitors by Total Liabilities
The table below lists competitors of Aldeyra The ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Concorde International Group Ltd.
NASDAQ:YOOV
|
USA | $10.17 Million |
|
Critical Holdings Berhad
KLSE:0291
|
Malaysia | RM75.50 Million |
|
Loxley Public Company Limited
BK:LOXLEY
|
Thailand | ฿6.19 Billion |
|
Vacasa Inc
NASDAQ:VCSA
|
USA | $468.78 Million |
|
Buda Juice, Inc.
NYSE MKT:BUDA
|
USA | $1.23 Million |
|
Monroe Capital Corp
NASDAQ:MRCC
|
USA | $215.91 Million |
|
Concorde International Group Ltd Class A Ordinary Shares
NASDAQ:CIGL
|
USA | $10.17 Million |
|
Comet Ridge Ltd
AU:COI
|
Australia | AU$47.06 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Aldeyra The's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Aldeyra The.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aldeyra The's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aldeyra The (2011–2024)
The table below shows the annual total liabilities of Aldeyra The from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $33.60 Million | +17.77% |
| 2023-12-31 | $28.53 Million | -5.78% |
| 2022-12-31 | $30.28 Million | +10.52% |
| 2021-12-31 | $27.40 Million | +14.92% |
| 2020-12-31 | $23.84 Million | -13.09% |
| 2019-12-31 | $27.44 Million | +223.80% |
| 2018-12-31 | $8.47 Million | +85.25% |
| 2017-12-31 | $4.57 Million | +29.29% |
| 2016-12-31 | $3.54 Million | +6.36% |
| 2015-12-31 | $3.33 Million | +32.90% |
| 2014-12-31 | $2.50 Million | +17.60% |
| 2013-12-31 | $2.13 Million | -92.16% |
| 2012-12-31 | $27.13 Million | +946.16% |
| 2011-12-31 | $2.59 Million | -- |
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatm… Read more